Literature DB >> 17475886

Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses.

Vera M Ripoll1, Katharine M Irvine, Timothy Ravasi, Matthew J Sweet, David A Hume.   

Abstract

The process of inflammation requires the selective expression of a suite of genes in cells of the macrophage lineage. To identify candidate regulators of inflammation, we used cDNA microarrays to compare the transcriptome of inflammatory macrophages (thioglycolate-elicited peritoneal macrophages), bone marrow-derived macrophages, nonadherent spleen cells, and fibroblasts. We identified genes that were macrophage restricted and further elevated in inflammatory macrophages, and characterized the function of one such gene, gpnmb. Gpnmb mRNA expression was enriched in myelomonocytic cell lines and macrophage-related tissues and strongly up-regulated during macrophage differentiation. Epitope-tagged GPNMB expressed in RAW264.7 cells exhibited a perinuclear distribution and colocalized with the Golgi marker coat protein beta. Upon activation of macrophages with IFN-gamma and LPS, GPNMB translocated from the Golgi apparatus to vesicular compartments scattered toward the periphery. Gpnmb overexpression in RAW264.7 cells caused a 2-fold reduction in the production of the cytokines IL-6 and IL-12p40 and the inflammatory mediator NO in response to LPS. DBA mice, which have an inactivating point mutation in the gpnmb gene, exhibited reduced numbers of myeloid cells, elevated numbers of thioglycolate-elicited peritoneal macrophages, and higher levels of proinflammatory cytokines in response to LPS. Thus, GPNMB acts as a negative regulator of macrophage inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475886     DOI: 10.4049/jimmunol.178.10.6557

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  87 in total

1.  Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression.

Authors:  Fangyuan Shi; Shuangyan Duan; Jihong Cui; Xingrong Yan; Hongmin Li; Yingjuan Wang; Fulin Chen; Lihua Zhang; Jun Liu; Xin Xie
Journal:  J Mol Neurosci       Date:  2014-03-30       Impact factor: 3.444

2.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

3.  Rapid temporal dynamics of transcription, protein synthesis, and secretion during macrophage activation.

Authors:  Katrin Eichelbaum; Jeroen Krijgsveld
Journal:  Mol Cell Proteomics       Date:  2014-01-06       Impact factor: 5.911

4.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Authors:  Patrick A Ott; Omid Hamid; Anna C Pavlick; Harriet Kluger; Kevin B Kim; Peter D Boasberg; Ronit Simantov; Elizabeth Crowley; Jennifer A Green; Thomas Hawthorne; Thomas A Davis; Mario Sznol; Patrick Hwu
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

5.  Western blot patterns of serum autoantibodies against optic nerve antigens in dogs with goniodysgenesis-related glaucoma.

Authors:  Stephanie A Pumphrey; Stefano Pizzirani; Christopher G Pirie; M Sawkat Anwer; Tanya Logvinenko
Journal:  Am J Vet Res       Date:  2013-04       Impact factor: 1.156

6.  Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.

Authors:  Toshihiko Hoashi; Shinichi Sato; Yuji Yamaguchi; Thierry Passeron; Kunihiko Tamaki; Vincent J Hearing
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

7.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.

Authors:  Madeleine V Pahl; Nosratola D Vaziri; Jun Yuan; Sharon G Adler
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

8.  Genomics and proteomics approaches to the study of cancer-stroma interactions.

Authors:  Flávia C Rodrigues-Lisoni; Paulo Peitl; Alessandra Vidotto; Giovana M Polachini; José V Maniglia; Juliana Carmona-Raphe; Bianca R Cunha; Tiago Henrique; Caique F Souza; Rodrigo A P Teixeira; Erica E Fukuyama; Pedro Michaluart; Marcos B de Carvalho; Sonia M Oliani; Eloiza H Tajara; P M Cury; M B de Carvalho; E Dias-Neto; D L A Figueiredo; E E Fukuyama; J F Góis-Filho; A M Leopoldino; R C M Mamede; P Michaluart-Junior; R A Moyses; F G Nóbrega; M P Nóbrega; F D Nunes; E F B Ojopi; L N Serafini; P Severino; A M A Silva; W A Silva; N J F Silveira; S C O M Souza; E H Tajara; V Wünsch-Filho; A Amar; C M Bandeira; M A Braconi; L G Brandão; R M Brandão; A L Canto; M Cerione; R Cicco; M J Chagas; H Chedid; A Costa; B R Cunha; O A Curioni; C S Fortes; S A Franzi; A P Z Frizzera; D Gazito; P E M Guimarães; C M Kaneto; R V M López; R Macarenco; M R Magalhães; C Meneses; A M C Mercante; D G Pinheiro; G M Polachini; A Rapoport; C O Rodini; F C Rodrigues-Lisoni; R V Rodrigues; L Rossi; A R D Santos; M Santos; F Settani; F A M Silva; I T Silva; T B Souza; E Stabenow; J T Takamori; P J Valentim; A Vidotto; F C A Xavier; F Yamagushi; M L Cominato; P M S Correa; G S Mendes; R Paiva; O Ramos; C Silva; M J Silva; M V C Tarlá
Journal:  BMC Med Genomics       Date:  2010-05-04       Impact factor: 3.063

9.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 10.  Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Authors:  Aiko Nagayama; Leif W Ellisen; Bruce Chabner; Aditya Bardia
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.